<DOC>
	<DOCNO>NCT00303823</DOCNO>
	<brief_summary>This randomized phase II trial study green tea extract see well work compare placebo prevent cervical cancer patient human papillomavirus low-grade cervical intraepithelial neoplasia . Chemoprevention use certain substance keep cancer forming , grow , come back . The use green tea extract may stop cervical cancer form patient human papillomavirus low-grade cervical intraepithelial neoplasia . It yet know whether green tea extract effective placebo prevent cervical cancer patient human papillomavirus low-grade cervical intraepithelial neoplasia .</brief_summary>
	<brief_title>Green Tea Extract Preventing Cervical Cancer Patients With Human Papillomavirus Low-Grade Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess effect green tea extract ( Polyphenon E® ) patient human papillomavirus ( HPV ) expression low-grade cervical intraepithelial neoplasia ( CIN 1 ) pre- post-treatment setting . SECONDARY OBJECTIVES : I . Compare toxicity green tea extract v placebo among patient CIN 1 . TERTIARY OBJECTIVES : I . Evaluate utility karyometry intermediate endpoint biomarker cervical chemoprevention study . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients randomize 1 2 treatment arm . ARM I : Patients receive oral green tea extract ( Polyphenon E® ) daily 16 week absence unacceptable toxicity . ARM II : Patients receive oral placebo daily 16 week absence unacceptable toxicity . After completion study treatment , patient follow 2 week .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Histologically confirm cervical intraepithelial neoplasia 1 ( CIN 1 ) AND oncogenic human papillomavirus ( HPV ) positivity At increase risk develop cervical cancer due &gt; = 1 follow criterion ( document 612 month ago ) * : Positive oncogenic HPV DNA hybrid capture Lowgrade squamous intraepithelial lesion cytology Histopathologically document CIN 1 cervical biopsy [ Note : *Patients must current CIN 1 histology colposcopy AND HPV positivity ] Cervical dysplasia colposcopy OR positive biopsy No invasive cervical cancer highgrade intraepithelial neoplasia cervical biopsy endocervical curettage ECOG performance status &lt; 2 Total bilirubin &lt; 2 time upper limit normal ( ULN ) AST &lt; 2 time ULN ALT normal Creatinine &lt; 2.0 mg/dL Able willing return clinic study visit every 4 week duration study No history allergic reaction tea related dietary product No HIV positive patient ( AIDS/HIVassociated complex ) No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection HPV Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement No history cancer except nonmelanoma skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No regular intake 6 serving tea per week within 1 month prior study entry No treatment genital condyloma within 30 day prior study entry No prior pelvic irradiation No concurrent tea ( green , black , oolong ) teaderived product No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>